ARGX (argenx SE) Forward P/E Multiple
argenx SE is exposed to global supply chain disruption risks and regulatory barriers. However, its success relies on a unique antibody platform for combating autoimmune pathologies. The issuer's forward P/E and daily price action on the GURU.Markets chart demonstrate valuation dynamics, where 25.60 indicates the current level. A steady inflow of operating cash from new sales reduces the need for borrowed funds.
Analytical breakdowns for argenx SE
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- debt and liquidity details:
- company profitability and valuation multiples indicators:
ARGX - Final Profit|Projected Future Earnings argenx SE|ARGX - Market Cap to Net Income Ratio|Forward P/E Multiple argenx N.V.|ARGX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization argenx SE|ARGX - Operating profit before amortization|Net earnings per share for the last 12 months argenx|ARGX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months argenx.com|ARGX - Earnings per share increase in current year|Net earnings per share growth forecast for next year argenx SE
- total revenue and sales volume data:
Summary company analytics:argenx.com
The successful implementation of immunological drugs provides argenx SE with a steady cash flow. By analyzing the company's forward P/E multiple, an investor sees the ratio of the current share price to expected future earnings. This indicator measures market expectations regarding business growth rates. A declining ratio amid rising revenue signals that the asset is undervalued. Inelastic demand for rare disease therapies confirms the fundamental strength of the company.
Competitors of argenx SE (ARGX)
Projected Price to Earnings BNTX (BioNTech Group)|ABVX (abivax.com) - Future Price to Earnings Multiple|Forward P/E Multiple ADMA (admabiologics.com)|Market Cap to Projected Earnings protagonist-inc.com (PTGX)|IMVT - Future Price to Earnings|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Projected Price to Earnings|Grifols Biemat (GRFS) - Future Price to Earnings|Projected Price to Earnings Adaptive Biotechnologies|Projected Price to Earnings CLDX|Forward P/E Multiple auriniapharma.com|Future Price to Earnings BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Future Earnings Ratio|Forward P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Projected Price to Earnings Ratio|AbCellera Biologics - Forward P/E Multiple|tourmalinebio.com - Market Cap to Future Earnings Ratio|Precigen (PGEN) - Future Price to Earnings|Pharming Group - Future Price to Earnings Multiple|Future Price to Earnings Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ZBIO|Forward P/E Multiple immunome.com (IMNM)|Forward P/E Multiple GOSS (gossamerbio.com)|Market Cap to Projected Earnings KalVista Pharma (KALV)|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple
